Literature DB >> 20047993

Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?

Suree Lekawanvijit1, Anastasia Adrahtas, Darren J Kelly, Andrew R Kompa, Bing H Wang, Henry Krum.   

Abstract

AIMS: Indoxyl sulfate (IS) is a uraemic toxin found at high concentration in patients with chronic kidney disease (CKD) co-morbid with chronic heart failure (CHF). The aim of this study was to determine direct effects of IS on cardiac cells as well as the pro-inflammatory effect of IS. METHODS AND
RESULTS: Indoxyl sulfate significantly increased neonatal rat cardiac fibroblast collagen synthesis (by 145.7% vs. control, P < 0.05) and myocyte hypertrophy (by 134.5% vs. control, P < 0.001) as determined by (3)H-proline or (3)H-leucine incorporation, respectively. Indoxyl sulfate stimulated tumour necrosis factor-alpha, interleukin-6 (IL-6), and IL-1beta mRNA expression in THP-1 cells as quantified by RT-PCR. Both p38 (RWJ-67657) and MEK1/2 (U0126) inhibitors suppressed all these effects by IS. Furthermore, western blot analysis showed that IS activated mitogen-activated protein kinase (MAPK) (p38, p42/44) and nuclear factor-kappa B (NFkappaB) pathways. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that IS exerted its effects without affecting cell viability.
CONCLUSION: This study has, for the first time, demonstrated that IS has pro-fibrotic, pro-hypertrophic, and pro-inflammatory effects, indicating that IS might play an important role in adverse cardiac remodelling mediated via activation of the p38 MAPK, p42/44 MAPK, and NFkappaB pathways. Targeting reduction of IS and/or the pathways it activates may represent a novel therapeutic approach to the management of CHF with concomitant CKD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047993     DOI: 10.1093/eurheartj/ehp574

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  97 in total

1.  Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction.

Authors:  Hideki Fujii; Yuriko Yonekura; Yusuke Yamashita; Keiji Kono; Kentaro Nakai; Shunsuke Goto; Mikio Sugano; Sumie Goto; Ayako Fujieda; Yoshiharu Ito; Shinichi Nishi
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

Review 2.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 3.  Klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

4.  Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Authors:  Liesbeth Viaene; Björn K I Meijers; Bert Bammens; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

Review 5.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

6.  DNA hypermethylation of sFRP5 contributes to indoxyl sulfate-induced renal fibrosis.

Authors:  Yanlin Yu; Xu Guan; Ling Nie; Yong Liu; Ting He; Jiachuan Xiong; Xinli Xu; Yan Li; Ke Yang; Yiqin Wang; Yunjian Huang; Bing Feng; Jingbo Zhang; Jinghong Zhao
Journal:  J Mol Med (Berl)       Date:  2017-05-15       Impact factor: 4.599

7.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.

Authors:  Celine Valant; Lauren T May; Luigi Aurelio; Chung Hui Chuo; Paul J White; Jo-Anne Baltos; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-11       Impact factor: 11.205

Review 8.  Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis.

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  J Card Fail       Date:  2015-10-03       Impact factor: 5.712

Review 9.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

Review 10.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.